Avacopan for the Treatment of ANCA-Associated Vasculitis | NEJM

The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis. In this randomized, controlled trial, we assigned patient…

Read the full article here

Related Articles